Blockchain Registration Transaction Record
Soligenix's Promising Biopharmaceutical Breakthroughs Highlighted in Zacks Report
Soligenix (SNGX) advances in rare disease treatments with HyBryte(TM) for CTCL, as highlighted in a Zacks report. Key milestones expected in 2025-2026.

This news is significant for investors, healthcare professionals, and patients alike, as it highlights Soligenix's potential to introduce groundbreaking treatments for rare diseases. The company's progress in clinical trials could lead to new, effective therapies for conditions with limited treatment options, offering hope to patients worldwide. Additionally, the anticipated milestones in 2025 and 2026 present key investment opportunities in the biopharmaceutical sector.
Blockchain | Details |
---|---|
Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
Transaction ID | 0x0a333b5bedfacd3360d1c1be541d06a24330972a72e577646bf98058af513015 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | fastNRMw-a00585cb51a299e34b8716ce448e878b |